Welcome to the summer 2025 newsletter from the KRAS Patient Gateway—your place for the latest research and information about KRAS-positive lung cancer.
Non-small cell lung cancer (NSCLC) with a KRAS G12C mutation is treated with immunotherapy as the first treatment approach. If the cancer begins to grow again, two targeted therapy drugs, adagrasib and sotorasib, are available for treatment.
Building on previous success, scientists are optimizing treatment for KRAS G12C targeted therapy. In data presented earlier this month at the annual American Society of Clinical Oncology meeting, researchers report that a combination of adagrasib and pembrolizumab (a type of immunotherapy) improve progression-free survival in newly diagnosed patients. This promising approach is already being expanded into two global clinical trials (KRYSTAL-7 and KRYSTAL-4) that are currently enrolling patients.
A second-generation KRAS-directed drug, olomorasib, is being studied to improve outcomes for newly diagnosed patients with advanced KRAS G12C+ NSCLC, with encouraging results. This research continues in SUNRAY-01, a global clinical trial that is also currently enrolling patients.
As researchers learn more about mutations that drive the development and growth of cancer such as KRAS G12C, they have also made progress learning about important biomarkers that may predict how effective the treatment will be. Biomarkers that co-occur with the KRAS G12C mutation, such as mutations in the STK11 gene or high levels of TTF-1 protein expression, might help us predict the effectiveness of some types of treatment, such as targeted therapy or immunotherapy, respectively.
Beyond the KRAS G12C mutation, researchers are also working hard to develop treatments for other KRAS alterations (such as KRAS G12D).
For 40 years, KRAS+ NSCLC was considered “undruggable”—and now we have immunotherapy and two KRAS G12C targeted therapies, adagrasib and sotorasib, as options for treatment.
Stay tuned for more updates in this space as researchers continue to work to improve the way we treat patients with KRAS+ NSCLC.
Research News
Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC
Lung Cancer News Today
June 11, 2025
New Biomarker Offers Insight for Optimizing KRAS Inhibitor Therapy in Lung
Scienmag
May 28, 2025
Pooled Safety Analysis and Management of Sotorasib-Related Adverse Events in Kras G12C-Mutated Advanced Non-small Cell Lung Cancer
Digitalcommons@TMC
May 27, 2025
Get Connected
Join Us for the KRAS Virtual Meetup
This is an easy way to build your community. On the third Wednesday of each month, you can connect with others who understand what it’s like to live with KRAS+ lung cancer. The next KRAS Meetup is happening on July 16, 2025, at 12 pm ET. Register for free to get a confirmation email with details about how to join the virtual meeting. New attendees are always welcome and encouraged to join!
Can’t make it? Don’t worry, there’s a full list of virtual meetups to fit your schedule.
Save the Date!
September 26-27, 2025
International Lung Cancer Survivorship Conference
This free, virtual conference will give you a better understanding of the science behind your disease so you can collaborate more effectively with your healthcare team. Connect in real time with specialists and patient advocates who understand your specific diagnosis, hear inspiring survivor stories, and learn how to use your voice in research and policy advocacy.
Be the first to know when registration opens.
Have You Seen?
Fill Your Home with HOPE
For the first time ever, LUNGevity has recorded sessions from our annual HOPE Summit so you can hear the inspiring stories from lung cancer survivors, gain important information from reliable experts and hear about the important advances in treating disease—from the comfort of your home. Learn more.
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
Does aromatherapy actually work? Can regular yoga practice be done during lung cancer treatment? The answers to these questions (and more) are being studied by lung cancer experts. Integrative oncology is about how to safely incorporate nutritional supplements and other complementary therapy into your treatment plan. Learn more.
Staying Safe From Smoke, Pollution,
and Dangerous Air Quality
Angela Hopper is a lung cancer survivor and an air quality expert who shares useful tips on navigating poor air quality. Learn more.
…and there is always so much more to explore on the KRAS Patient Gateway.
If you were forwarded this email and you’d like to subscribe to this newsletter, you can sign up here.
If you need further assistance along your lung cancer journey, please email us at support@lungevity.org. Our team is always here to assist you.
